Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

MAIA Biotechnology Inc.

Healthcare US MAIA

1.27USD
-0.09(6.62%)

Last update at 2026-06-08T20:24:00Z

Day Range

1.271.38
LowHigh

52 Week Range

0.825.22
LowHigh

Fundamentals

  • Previous Close 1.36
  • Market Cap18.66M
  • Volume609867
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.44

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -15.76928M -12.57821M -6.95925M -
Minority interest 0.00000M 0.07M 0.32M -
Net income -15.80597M -13.28574M -6.66821M -
Selling general administrative 6.14M 4.29M 5.56M -
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation - - - -
Ebit -16.17620M -7.78663M -6.97560M -6.92136M
Ebitda -15.86071M -7.74095M -6.97492M -
Depreciation and amortization 0.32M 0.05M 0.00068M -
Non operating income net other - - - -
Operating income -16.17620M -7.78663M -6.97560M -
Other operating expenses 15.86M 7.74M 6.98M -
Interest expense 0.00697M 0.83M 0.03M 0.00000M
Tax provision - - - -
Interest income 0.00187M 0.00201M 0.00068M -
Net interest income -0.00510M -0.82553M -0.03155M -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.04M 0.71M -0.29104M -
Total revenue 0.00000M 0.00000M 0.00000M -
Total operating expenses 15.86M 7.74M 6.98M -
Cost of revenue - - - -
Total other income expense net 0.41M -4.79158M 0.02M -
Discontinued operations - - - -
Net income from continuing ops -15.76928M -12.57821M -6.95925M -
Net income applicable to common shares - -12.50388M -6.63666M -6.49278M
Preferred stock and other adjustments - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 12.02M 11.33M 0.75M -
Intangible assets - - - -
Earning assets - - - -
Other current assets 0.55M 0.10M 0.08M -
Total liab 3.51M 2.15M 2.36M -
Total stockholder equity 8.51M 9.18M -3.33609M -
Deferred long term liab - 0.65M - -
Other current liab 2.10M 1.19M 1.51M 0.00210M
Common stock 0.00110M 0.00076M 0.00044M 0.00044M
Capital stock 0.00110M 0.00076M 0.00044M -
Retained earnings -44.20727M -28.43799M -15.93411M -9.29745M
Other liab - - 0.24M 0.03M
Good will - - - -
Other assets - 0.65M - -
Cash 10.95M 10.57M 0.66M -
Cash and equivalents - - - -
Total current liabilities 3.27M 2.15M 1.69M 0.37M
Current deferred revenue - - - -
Net debt -10.95093M -10.57429M -0.19970M -
Short term debt - - 0.03M -
Short long term debt - - 0.03M -
Short long term debt total - - 0.46M -
Other stockholder equity 52.73M 37.62M 12.60M -0.10440M
Property plant equipment - - - -
Total current assets 11.81M 10.67M 0.75M 1.73M
Long term investments - - - -
Net tangible assets - 9.18M -3.33609M -0.17287M
Short term investments - - - -
Net receivables 0.30M - - -
Long term debt - - 0.43M -
Inventory - - - -
Accounts payable 1.17M 0.96M 0.15M 0.17M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income -0.01597M - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other 0.21M 0.65M - -
Deferred long term asset charges - - - -
Non current assets total 0.21M 0.65M 0.00000M -
Capital lease obligations - - - -
Long term debt total - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments - - - -
Change to liabilities - 0.81M -0.00230M 0.10M
Total cashflows from investing activities - - - 0.19M
Net borrowings - 7.43M 0.67M 0.04M
Total cash from financing activities 12.04M 14.03M 0.80M 2.22M
Change to operating activities - 0.32M 1.26M 0.16M
Net income -15.76928M -12.57821M -6.95925M -6.49278M
Change in cash 0.38M 9.91M -1.04611M 0.84M
Begin period cash flow 10.57M 0.66M 1.71M -
End period cash flow 10.95M 10.57M 0.66M 1.71M
Total cash from operating activities -11.65573M -4.12290M -1.84416M -1.56511M
Issuance of capital stock 13.97M 5.74M 0.05M -
Depreciation - - - -
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - - - -
Other cashflows from financing activities -1.93677M 8.29M 0.75M 0.17M
Change to netincome - 6.66M 3.52M 4.66M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 0.79M 1.13M 1.25M -
Stock based compensation 2.32M 2.72M 3.89M -
Other non cash items 1.00M 4.61M -0.02803M -
Free cash flow -11.65573M -4.12290M -1.84416M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
MAIA
MAIA Biotechnology Inc.		 -0.09 6.62% 1.27 - - - 6.24 -0.9594
NVO
Novo Nordisk A/S		 -1.94 4.52% 41.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.11 4.87% 41.25 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.87 0.87% 442.96 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -24.11 3.79% 611.34 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.

MAIA Biotechnology Inc.

444 West Lake Street, Chicago, IL, United States, 60606

Key Executives

Name Title Year Born
Dr. Vlad Vitoc M.B.A., M.D. Co-Founder, Pres, CEO & Chairman of Directors 1970
Mr. Joseph F. McGuire Chief Financial Officer 1958
Dr. Mihail Obrocea M.D. Chief Medical Officer & Head of Devel. 1959
Dr. Sergei M. Gryaznov Ph.D. Chief Scientific Officer 1960
Linda Moreira Company Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.